Syndax Pharmaceuticals
SNDX
8.72
-0.41
-4.49%
Syndax Pharmaceuticals
US · SNDX
#2947 by market cap
Listed 2016
8.72
-0.41
-4.49%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 3.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 119.84% -3.62pp
- Institutions
- 303
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund57.39%
Hedge Fund41.43%
Public Company10.19%
VC/PE Fund6.16%
Private Company2.14%
Individual/Insider0.88%
Endowment Fund0.83%
Insurance Company0.78%
Family Office/Trust0.34%
Government Pension Fund0.58%
Top holders as of 2026-09-30
BlackRock
10.30% · 9.27M sh
Kynam Capital Management, LP
8.94% · 8.05M sh
The Goldman Sachs Group, Inc.
6.04% · 5.44M sh
State Street Global Advisors
5.17% · 4.65M sh
Vanguard Capital Management, LLC
4.39% · 3.95M sh
Deerfield Management Company, L.P.
4.20% · 3.78M sh
Franklin Resources
3.87% · 3.49M sh
Eversept Partners, L.P.
3.11% · 2.80M sh
Bank of America Corporation
2.91% · 2.62M sh
Geode Capital Management, LLC
2.89% · 2.58M sh
Hood River Capital Management LLC
2.85% · 2.56M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Keith Katkin | Independent Director | 0.10% |
| Pierre Legault | Independent Director | 0.10% |
| Jennifer Jarrett | Independent Director | 0.10% |
| Martin Huber | Independent Director | 0.08% |
| Michael Metzger | Chief Executive Officer | 0.07% |
| Nicholas Botwood | Head of Research & Development and Chief Medical Officer | 0.07% |
| Keith Goldan | Officer | 0.03% |
| Aleksandra Rizo | Independent Director | 0.03% |
| Dennis Podlesak | Independent Chairperson | 0.02% |
| Neil Gallagher | Former President and Head of Research & Development | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | Aaron Ondrey | CFO, Principal Accounting and Financial Officer & Treasurer | Other Derivative Acquisition | +270,000 | $9.55 |
| 2026-10-28 | Dennis Podlesak | Independent Chairperson | Derivative Exercise and Sale | -8,000 | $11.81–14.21 |
| 2026-07-07 | Michael Metzger | Chief Executive Officer | Derivative Exercise and Sale | -32,375 | $6.38–24.24 |
| 2026-06-11 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -53,750 | $13.82–18.14 |
| 2026-06-11 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -31,235 | $18.14 |
| 2026-06-10 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Automatic Disposition | -11,765 | $18.00 |
| 2026-05-31 | Keith Goldan | Officer | Open Market Disposition | -1,177 | $18.99 |
| 2026-05-31 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -6,847 | $18.99 |
| 2026-02-08 | Keith Goldan | Officer | Open Market Disposition | -3,410 | $21.03 |
| 2026-02-08 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -17,159 | $21.03 |
| 2026-02-05 | Keith Goldan | Officer | Open Market Disposition | -2,082 | $20.62 |
| 2026-02-05 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -7,412 | $20.62 |
| 2026-02-03 | Keith Katkin | Independent Director | Other Acquisition | +24,000 | -- |
| 2026-02-03 | Pierre Legault | Independent Director | Other Acquisition | +24,000 | -- |
| 2026-02-03 | Keith Goldan | Officer | Other Acquisition | +52,250 | -- |
| 2026-02-03 | Keith Goldan | Officer | Other Derivative Acquisition | +118,000 | $20.43 |
| 2026-02-03 | Dennis Podlesak | Independent Chairperson | Other Acquisition | +48,000 | -- |
| 2026-02-03 | Michael Metzger | Chief Executive Officer | Other Acquisition | +217,600 | -- |
| 2026-02-03 | Michael Metzger | Chief Executive Officer | Other Derivative Acquisition | +440,000 | $20.43 |
| 2026-02-03 | Jennifer Jarrett | Independent Director | Other Acquisition | +24,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.
Syndax Pharmaceuticals discussion 0 comments